TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.98 USD | -1.96% |
|
+1.16% | -18.15% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| Apr. 18 | Sector Update: Health Care | MT |
Presenter SpeechMichael Weiss (Executives)Okay. I think we'll get started if everyone is ready...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.98
USD
Average target price
29.75
USD
Spread / Average Target
+112.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.15% | 2.16B | |
| +4.09% | 43.84B | |
| +46.85% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- Transcript : TG Therapeutics, Inc. - Shareholder/Analyst Call
